Laura Shawver - 05 Aug 2022 Form 4 Insider Report for Silverback Therapeutics, Inc. (SPRY)

Role
Chief Executive Officer, Director
Signature
/s/ Jeffrey C. Pepe, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
05 Aug 2022
Net transactions value
+$100,000
Form type
4
Filing time
09 Aug 2022, 16:38:07 UTC
Previous filing
10 Jun 2022
Next filing
10 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $100,000 +78,740 +45% $1.27* 254,242 05 Aug 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock option (right to buy) Options Exercise $0 -78,740 -16% $0.000000 402,997 05 Aug 2022 Common Stock 78,740 $1.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares vested on April 16, 2021 and the remaining shares shall vest in 36 equal monthly installments thereafter.